ClinicalTrials.gg
CompletedNCT01311622Updated Jan 31, 2013

Effects of Administration of Fostamatinib on Blood Concentrations of Warfarin in Healthy Subjects

A Phase 1 interventional study of warfarin and fostamatinib in Rheumatoid Arthritis and Healthy Subjects, sponsored by AstraZeneca. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2013-01-31.

Sponsored by AstraZeneca · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
15
Allocation
Non-randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 49 studies in Arthritis, Rheumatoid by AstraZeneca — 4 open to participants now, 4 under way, none of them phase 3. Arthritis, Rheumatoid · AstraZeneca.

Enrollment
40th of 45
15 · median 72
Started
2011
with 7 others
Phase 1
22 of 49
2 open now
Registered
22nd of 49
by date

Among the 49 studies in Arthritis, Rheumatoid by AstraZeneca, this one is the 40th largest by enrollment of the 45 interventional ones that give a count, is one of 8 that started in 2011, is one of 22 in phase 1, and was the 22nd registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 444 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

4 of the 49 studies in Arthritis, Rheumatoid by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 49 studies in Arthritis, Rheumatoid by AstraZeneca, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether fostamatinib influences the plasma concentration of warfarin and changes its blood thinning effect, and to investigate how safe and tolerable it is when administered with warfarin.

03

Conditions studied

  • Rheumatoid Arthritis
  • Healthy Subjects

Keywords

  • drug-drug interaction
  • Phase 1
  • healthy subjects
  • warfarin
  • Rheumatoid arthritis
  • RA
  • fostamatinib open-label
  • pharmacokinetics
  • pharmacodynamics
  • level of Warfarin in the blood
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provision of prior to any study specific procedures (including genotyping screening sample for CYP2C9 and VKORC1).
  • Males or females (of non-) aged 18 to 55 years (inclusive)
  • Subjects must be negative for occult blood (stool card) prior to administration.
  • Body weight of at least 50 kg and (BMI) between 18 and 35 kg/m2 inclusive

Exclusion criteria

Exclusion Criteria:

  • History of any disease or disorder which, in the opinion of the Investigator, may put the subject at risk because of participation in the study, or influence the results of the study.
  • Healthy subject predicted to be most sensitive to warfarin based on CYP2C9 and VKORC1 genotypes.
  • A protein C and/or protein S deficiency.
  • of less than 2500/mm3 or 2.5 x 109/L
  • Previous treatment with warfarin for a clinical indication (ie, participation in a previous warfarin interaction study is acceptable).
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    warfarin

    Drug: warfarin

  • Experimental
    warfarin and fostamatinib

    Drug: warfarin · Drug: fostamatinib

Interventions

  • 2 single 25 mg doses of Warfarin (5 x 5 mg tablets) administered 14 days apart

    Also known as: Marevan

  • 2 x 50 mg Fostamatinib tablets (100 mg) twice daily for 13 days

06

What researchers measure

Primary outcomes

  1. To determine PK parameters of R- and S-warfarin including but not limited to AUC and Cmax

    * Pharmacokinetics of warfarin measured by AUC * Pharmacokinetics of warfarin measured Cmax

    Time frame: From pre-dose to 168 h post dose relative to each single warfarin dose

Secondary outcomes

  1. To measure International Normalised Ratio (INR) following administration of warfarin

    Time frame: From pre-dose to 168 h post dose relative to each single warfarin dose

  2. To assess the steady-state pharmacokinetics of R406 (active metabolite of fostamatinib) by measuring AUCss, Cmax,ss, tmax,ss and CL/F

    * Steady state Pharmacokinetics of R406 measured by AUCss * Steady state Pharmacokinetics of R406 measured by Cmax * Steady state Pharmacokinetics of R406 measured by ss * Steady state Pharmacokinetics of R406 measured by tmax * Steady state Pharmacokinetics of R406 measured by CL/F

    Time frame: From predose on Day 11 until 12 h post dose on Day 14 relative to fostamatinib dosing

  3. Safety and tolerability will be measured with regard to adverse events, laboratory assessments, vital signs, physical examination, and 12-lead ECG will be recorded.

    To examine the safety and tolerability of fostamatinib in combination with Warfarin: Adverse events, laboratory assessments, vital signs, physical examination, and 12-lead ECG

    Time frame: From screening, Day -1 to Day 21 and follow up visit (Day 28)

07

Study locations

1 site
  • Research Site
    London, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2011, a primary completion of May 2011 and a completion of May 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 21, 2011
First posted
Mar 9, 2011
Start
Mar 2011
Primary completionActual
May 2011
CompletionActual
May 2011
Last update
Jan 31, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 31, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01311622
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Mar 9, 2011
Start date
Mar 2011
Primary completion
May 2011
Completion
May 2011
Last update
Jan 31, 2013

Study contacts

James Ritter, BM BCh MRCP FRCP
principal investigator · Quintiles, Phase 1 Unit, London
Mark Layton, MD MRCP (UK)
study director · AstraZeneca
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Warfarin

Start the discussion